Elaine Chen is a reporter with a focus on medicine and healthcare at various esteemed publications. She covers a range of topics including alternative medicine, cannabis and psychedelics, nutrition, and the biotech market, often emphasizing the intersection of science and health. Elaine's work has been featured in BioRxiv, Yahoo Finance, Bloomberg News, and The New York Times, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Elaine Chen's coverage primarily focuses on healthcare, pharmaceuticals, and to a lesser extent finance. Her articles frequently cite data and press releases. Sources with access to relevant research findings or industry statistics may find success in pitching to her.
Given the prevalence of topics related to obesity, weight-loss drugs, and health research in her articles, Elaine would likely welcome insights from medical professionals specializing in these areas. Additionally, she might be interested in hearing from experts able to provide context around new developments within the pharmaceutical industry.
As Elaine does not have a specific geographic focus mentioned but covers international news across healthcare and finance sectors, she is likely open to receiving pitches from sources located anywhere globally who can offer valuable insights into these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Elaine Chen, Katie Palmer
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
By: Elaine Chen, Allison DeAngelis, Adam Feuerstein
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Some exciting
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, my colleagues
By: Elaine Chen
The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly's obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection.
By: Adam Feuerstein, Elaine Chen, Allison DeAngelis
By: Elaine Chen
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
(833) 317-6278 
